
Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib
Partnership aims to accelerate global access to almonertinib as a treatment for individuals with non-small cell lung cancer (NSCLC) Almonertinib is a 3rd generation EGFR […]


